SCHEMBL1918142

SCHEMBL1918142

O=C(O)c1ccc2c(c1)CCc1ccccc1C2=O

nearest known ligand 0.84

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SRD5A2 P31213 5/20 0.84
SRD5A1 P18405 4/20 0.84
TTR P02766 1/20 0.64
MITF O75030 1/20 0.57
HSP90AA1 P07900 1/20 0.57
RAB9A P51151 1/20 0.57
PTPRC P08575 2/20 0.57
CES1 P23141 1/20 0.55
MAPK14 Q16539 7/20 0.54
CHEK1 O14757 1/20 0.53
TDP1 Q9NUW8 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
POLB P06746 1/20 0.50
KMT2A Q03164 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10081754 0.91 SRD5A2 (1.00) SRD5A2SRD5A1TTRMITFHSP90AA1
SCHEMBL8253251 0.91 SRD5A2 (0.68) SRD5A2SRD5A1TTRMITFHSP90AA1
SCHEMBL9375041 0.90 SRD5A2 (0.68) SRD5A2SRD5A1TTRMITFHSP90AA1
SCHEMBL16126108 0.87 SRD5A2 (0.84) SRD5A2SRD5A1TTRRAB9APTPRC
SCHEMBL11686857 0.83 AKR1B1 (0.61) SRD5A2SRD5A1TTRMAPK14
SCHEMBL11684328 0.83 AKR1B1 (0.64) SRD5A2SRD5A1TTRMAPK14
SCHEMBL11683923 0.82 SRD5A2 (0.57) SRD5A2SRD5A1TTRHSP90AA1PTPRC
SCHEMBL11685606 0.82 MAPK14 (0.60) SRD5A2SRD5A1TTRPTPRCMAPK14
SCHEMBL11683555 0.82 SRD5A2 (0.57) SRD5A2SRD5A1TTRPTPRCMAPK14
SCHEMBL11689203 0.82 SRD5A2 (0.57) SRD5A2SRD5A1TTRPTPRCMAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3081213-B1 TRICYCLIC COMPOUND KYOWA KIRIN CO LTD (JP) 2020-04-01 EP disclosed
US-9475805-B2 Tricyclic compound KYOWA HAKKO KIRIN CO., LTD. (JP) 2016-10-25 US disclosed
EP-3081213-A1 TRICYCLIC COMPOUND Kyowa Hakko Kirin Co., Ltd. (JP) 2016-10-19 EP disclosed
US-20150291587-A1 TRICYCLIC COMPOUND KYOWA KIRIN CO., LTD. (JP) 2015-10-15 US disclosed
EP-1988091-B1 TRICYCLIC COMPOUNDS KYOWA HAKKO KIRIN CO LTD (JP) 2015-06-10 EP disclosed
US-20130267711-A1 TRICYCLIC COMPOUND KYOWA HAKKO KIRIN CO LTD (JP) 2013-10-10 US disclosed
US-8486980-B2 Tricyclic compound KYOWA HAKKO KIRIN CO., LTD. (JP) 2013-07-16 US disclosed
US-8242151-B2 Tricyclic compounds KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-08-14 US disclosed
US-8076330-B2 Dipeptidyl peptidase-IV inhibitors AMGEN INC. (US) 2011-12-13 US disclosed
US-20110201640-A1 TRICYCLIC COMPOUND KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-08-18 US disclosed
EP-2327690-A1 TRICYCLIC COMPOUND Kyowa Hakko Kirin Co., Ltd. (JP) 2011-06-01 EP disclosed
US-20110112051-A1 Dipeptidyl Peptidase-IV Inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2011-05-12 US disclosed
US-20090176760-A1 TRICYCLIC COMPOUNDS KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-07-09 US disclosed
EP-1988091-A1 TRICYCLIC COMPOUNDS Kyowa Hakko Kogyo Co., Ltd (JP) 2008-11-05 EP disclosed
US-5607955-A TREATMENT OF HYPERTENSION, CONGESTIVE HEART FAILURE, RENAL FAILURE AND GLAUCOMA KYOWA HAKKO KOGYO CO., LTD. (JP) 1997-03-04 US disclosed
US-4051260-A ANTIINFLAMMATORY, ANALGESIC, ANTIPYRETIC SYNTEX (U.S.A.) INC. (US) 1977-09-27 US disclosed
US-4041173-A ANTI-ASTHMATIC AGENTS SYNTEX (U.S.A.) INC. (US) 1977-08-09 US disclosed
US-4038299-A ANTIINFLAMMATORY, ANALGESIC, ANTIPYRETIC SYNTEX (U.S.A.) INC. (US) 1977-07-26 US disclosed
US-3975540-A ANTIINFLAMMATORY, ANALGESIC, ANTIPYRETIC SYNTEX (U.S.A.) INC. (US) 1976-08-17 US disclosed
US-3966820-A ANALGESICS, ANTIINFLAMMATORY, ANTIPYRETICS SYNTEX (U.S.A.) INC. (US) 1976-06-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150291587-A1 TRICYCLIC COMPOUND PPARA, PPARG, PPARD SRD5A2 1433/4885SRD5A1 1120/4885TTR 3511/4885
US-20130267711-A1 TRICYCLIC COMPOUND PPARA, PPARG, PPARD SRD5A2 1433/4885SRD5A1 1120/4885TTR 3511/4885
US-20110201640-A1 TRICYCLIC COMPOUND PPARG, PPARA, PPARD SRD5A2 898/4885SRD5A1 767/4885TTR 3655/4885
US-20090176760-A1 TRICYCLIC COMPOUNDS PPARG, PPARD, PPARA SRD5A2 737/4885SRD5A1 816/4885TTR 3690/4885
US-20110112051-A1 Dipeptidyl Peptidase-IV Inhibitors DPP4, DPP3, DPP7 SRD5A2 1531/4885SRD5A1 2084/4885TTR 1122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.